The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHiscox Regulatory News (HSX)

Share Price Information for Hiscox (HSX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,166.00
Bid: 1,171.00
Ask: 1,172.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.085%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,166.00
HSX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Market update on COVID-19 exposure

22 Apr 2020 07:00

RNS Number : 4141K
Hiscox Ltd
22 April 2020
 

Hiscox Ltd market update on COVID-19 exposure

 

Hamilton, Bermuda (22 April 2020) - Acknowledging there remains material uncertainty due to the unprecedented events that are currently unfolding, Hiscox has conducted further analysis of its potential exposure to the COVID-19 pandemic and provides an update.

Hiscox is actively settling claims for event cancellation and abandonment, media and entertainment and other segments including travel. On the basis that disruption caused by restrictions on travel and mass gatherings continues for a six month period from March 2020, Hiscox expects to pay net claims totalling up to $150 million. In the event that restrictions on travel and mass gatherings are extended beyond six months, Hiscox expects that these claims could increase by an additional $25 million.

 

Hiscox is also receiving claims as a result of economic losses following government action to stop the spread of COVID-19. Like others in the industry, Hiscox UK's core small commercial package policies do not provide cover for business interruption as a result of the general measures taken by the UK government in response to a pandemic.

 

As described in its announcement on 15 April, Hiscox UK has approximately 10,000 customers that purchased cover for business interruption and have been directly impacted by mandated government premises closure to stop the spread of COVID-19. Over 70% of these customers have monthly revenues of less than £40,000 in a normal trading environment, with a significant proportion below £10,000 per month. The level of economic loss experienced is likely to be materially lower than reported revenues.

 

A number of UK policyholders have disputed the application of their policy in relation to business interruption. Hiscox recognises these are extremely difficult times for businesses and is determined to help provide greater certainty for customers. As a priority it will therefore work with the UK insurance industry, its regulators and its customers to seek means of expediting resolution through the range of independent mechanisms available.

 

Hiscox believes its business interruption exposure to COVID-19 is limited in Hiscox Europe and it has negligible exposure in Hiscox USA.

 

Hiscox UK and Hiscox Europe have a substantial catastrophe reinsurance programme.

Hiscox's capital, liquidity and funding positions remain robust and the Group remains operationally strong in the face of unprecedented global uncertainty presented by the COVID-19 pandemic. Hiscox expects this uncertainty and consequent capital contraction to influence rates across wholesale and reinsurance markets.

 

ENDS

 

For further information:

Hiscox Ltd

Marc Wetherhill, Group Company Secretary, Bermuda +1 441 278 8321

Kylie O'Connor, Group Communications Director, London +44 (0)20 7448 6656 

Ryan Thompson, Investor Relations Manager, London +44 (0)20 7448 6522 

Brunswick

Tom Burns +44 (0)20 7404 5959

Simone Selzer +44 (0)20 7404 5959

 

 

 

Notes to editors

 

Hiscox response to Covid-19: staff and society

Hiscox is committed to supporting the international response to this pandemic. The Group has over 95% of employees around the world working from home, and is supporting them through flexible working and the provision of mental health and wellbeing services. Wherever possible operations have been reorganised to deploy more employees to provide customer support. The Group has committed to stand by existing employees by retaining all current roles on full pay until at least the end of the year. Hiscox is not furloughing any staff, and has not accessed any government support schemes.

 

Hiscox is working with the rest of the insurance industry, including the Association of British Insurers, to identify where it can direct financial support that will have the most impact. Through the Hiscox Foundation, the Group is also supporting vulnerable groups via donations to established charities such as the Trussell Trust and Age UK and around the world we are donating to food banks, the Red Cross and Personal Protective Equipment (PPE) funds.

 

About the Hiscox Group

Hiscox is a global specialist insurer, headquartered in Bermuda and listed on the London Stock Exchange (LSE:HSX). Our ambition is to be a respected specialist insurer with a diverse portfolio by product and geography. We believe that building balance between catastrophe-exposed business and less volatile local specialty business gives us opportunities for profitable growth throughout the insurance cycle. 

 

The Hiscox Group employs over 3,100 people in 14 countries, and has customers worldwide. Through the retail businesses in the UK, Europe, Asia and the USA, we offer a range of specialist insurance for professionals and business customers as well as homeowners. Internationally traded, bigger ticket business and reinsurance is underwritten through Hiscox London Market and Hiscox Re & ILS.

 

Our values define our business, with a focus on people, courage, ownership and integrity. We pride ourselves on being true to our word and our award-winning claims service is testament to that. For more information, visit www.hiscoxgroup.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFLFVDSDILFII
Date   Source Headline
25th Mar 20243:37 pmRNSDirector/PDMR Shareholding
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20242:06 pmRNSNotice of 2024 AGM and 2023 Annual Report
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:30 amRNSSyndicates 33 and 6104 – results and estimates
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:01 amRNSAnnouncement of share repurchase programme
5th Mar 20247:00 amRNSFull Year Results
19th Feb 20245:48 pmRNSTR-1 Standard form-notification major shareholding
1st Feb 20244:34 pmRNSTotal Voting Rights
8th Jan 20243:07 pmRNSTotal Voting Rights
12th Dec 20234:44 pmRNSDirector/PDMR Shareholding
1st Dec 20234:40 pmRNSTotal Voting Rights
10th Nov 202311:30 amRNSSyndicates 33 and 6104 – results and estimates
8th Nov 20237:00 amRNSQ3 2023 Trading Statement
1st Nov 20235:20 pmRNSTotal Voting Rights
2nd Oct 20234:47 pmRNSTotal Voting Rights
27th Sep 20237:00 amRNSDivestment of DirectAsia
25th Sep 202312:30 pmRNSDirector/PDMR Shareholding
25th Sep 20239:00 amRNSApplication to be admitted to the Official List
12th Sep 20235:22 pmRNSAnnouncement of Scrip Reference Share Price
1st Sep 20237:00 amRNSDirector/PDMR Shareholding
11th Aug 20237:30 amRNSSyndicates 33 and 6104 - results and estimates
10th Aug 20237:00 amRNSDirector/PDMR Shareholding
4th Jul 20231:23 pmRNSTotal Voting Rights
21st Jun 20233:23 pmRNSDirector/PDMR Shareholding
16th Jun 202312:35 pmRNSDirector PDMR Shareholding
14th Jun 20231:19 pmRNSStandard form for notification of major holdings
13th Jun 20232:28 pmRNSDirector/PDMR Shareholding
9th Jun 20231:56 pmRNSApplication to be Admitted to Official List
9th Jun 202312:19 pmRNSApplication to be Admitted to Official List
8th Jun 20237:00 amRNSIFRS 17 restated results 2022
1st Jun 20235:10 pmRNSTotal Voting Rights
1st Jun 202312:12 pmRNSAnnouncement of Scrip Reference Share Price
30th May 20234:05 pmRNSDirector/PDMR Shareholding
30th May 20237:00 amRNSHiscox appoints Jonathan Bloomer Chair designate
23rd May 20233:26 pmRNSTR-1:Standard form-notification major shareholding
22nd May 202312:25 pmRNSTR-1:Standard form-notification major shareholding
15th May 20231:01 pmRNSSyndicates 33 and 6104 – results and estimates
12th May 20237:01 amRNSHiscox appoints new Independent Non Exec Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.